ORYZON Reports Financial Results and Corporate Update for Half Year Ended June 30th, 2026

Positive clinical data presented at EHA for iadademstat in first line acute myeloid leukemia (AML); iadademstat+azacitidine+venetoclax resulted in 100% ORR, 89% CRc and 78% CR,...